会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Method and system for managing programs for web service system
    • 用于管理Web服务系统的方法和系统
    • US20050172034A1
    • 2005-08-04
    • US10969101
    • 2004-10-19
    • Nobuyoshi SakaiAtsushi OhtakeJun Sugihara
    • Nobuyoshi SakaiAtsushi OhtakeJun Sugihara
    • G06F11/00G06F9/445G06F15/16G06F17/30
    • G06F16/95
    • When a message is transmitted to an information processing device from a communication unit, the method of this invention receives a response from the destination information processing device by the communication unit and checks whether an error has occurred which was caused by a change made to the interface definition information representing an interface with the information processing device. In the event of an error caused by a change made to the interface definition information, the method of this invention test-transmits to the information processing device from the communication unit a message to identify an input type at a location of that change. According to the location of change and a result of test transmission, the method of this invention changes a content of a program on a memory unit which transmits the messages to the information processing device.
    • 当从通信单元向信息处理设备发送消息时,本发明的方法从通信单元接收来自目的地信息处理设备的响应,并检查是否发生由接口发生的改变引起的错误 表示与信息处理装置的接口的定义信息。 在由于对接口定义信息的改变引起的错误的情况下,本发明的方法从通信单元向信息处理设备发送消息以在该变化的位置识别输入类型。 根据变更的位置和测试传输的结果,本发明的方法将发送消息的存储单元中的节目内容改变到信息处理设备。
    • 2. 发明授权
    • 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2, derivative,
manufacturing process thereof and its use
    • 2,5,6,7-四去甲-4,8-​​间间亚苯基PGI 2,其衍生物及其制备方法及其用途
    • US5401768A
    • 1995-03-28
    • US90995
    • 1993-07-13
    • Kiyotaka OhnoToshiya TakahashiAtsushi OhtakeHisanori WakitaShintaro Nishio
    • Kiyotaka OhnoToshiya TakahashiAtsushi OhtakeHisanori WakitaShintaro Nishio
    • C07D307/93C07D407/14C07D493/04A61K31/34
    • C07D407/14C07D307/93C07D493/04
    • Disclosed are 2,5,6,7-tetranor-4,8-inter-m-phemylene PGI.sub.2 derivatives such as 16-methyl-2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, 17-methyl-2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, 15-phenyl-2,5,6,7,16,17,18,19,20-nonanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, 16,16-dimethyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-16-phenoxy-2,5,6,7,17,18,19,20-octanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-16-phenoxy-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, and 3-decarboxy-3-hydroxymethyl-16-methyl-16-phenoxy-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, which are useful as pharmaceuticals.These compounds are useful as an antiulcer drug, antihypertensive drug, antithrombus drug or the like.
    • PCT No.PCT / JP88 / 01048 Sec。 371日期1989年8月14日 102(e)日期1989年8月14日PCT提交1988年10月14日PCT公布。 出版物WO89 / 03387 日期:1989年4月20日。公开的是2,5,6,7-四去甲-4,8-​​间m-亚氨​​基PGI 2衍生物,如16-甲基-2,5,6,7-四去甲-4,8- 间 - 亚苯基PGI 2及其甲酯,17-甲基-2,5,6,7-四酮-4,8-​​间 - 间 - 亚苯基PGI 2及其甲酯,15-苯基-2,5,6, 7,16,17,18,19,20-壬腈-4,8-​​间间 - 亚苯基PGI2,16-甲基-17-苯基-2,5,6,7,18,19,20-庚酮-4 ,8-间 - 间 - 亚苯基PGI2,16,16-二甲基-17-苯基-2,5,6,7,18,19,20-庚烷-4,8-​​间间苯撑PGI2,16-甲基 -16-苯氧基-2,5,6,7,17​​,18,19,20-辛腈-4,8-​​间间苯撑PGI2,16-甲基-16-苯氧基-2,5,6,7, 18,19,20-庚酮-4,8-​​间 - 间 - 亚苯基PGI 2及其甲酯和3-脱羧基-3-羟甲基-16-甲基-16-苯氧基-2,5,6,7,18, 19,20-庚酮-4,8-​​间间 - 亚苯基PGI2,其可用作药物。 这些化合物可用作抗溃疡药,抗高血压药,抗血栓药物等。
    • 4. 发明授权
    • Mass spectrometric analysis method and system using the method
    • 质谱分析方法和系统采用该方法
    • US07435949B2
    • 2008-10-14
    • US11439949
    • 2006-05-25
    • Atsushi OhtakeKinya KobayashiToshiyuki YokosukaKiyomi Yoshinari
    • Atsushi OhtakeKinya KobayashiToshiyuki YokosukaKiyomi Yoshinari
    • B01D59/44H01J49/26
    • H01J49/02H01J49/004
    • A tandem analysis system is provided for ionizing a substance, performing mass spectrometric analysis of various ion types generated, selecting and dissociating an ion type, the ion type having a specific mass-to-charge ratio, and thereby, repeating mass spectrometric analysis measurement on the ion of the ion type over n-th stages. A processing judges control content for the analysis next to MSn (the n-th stage mass spectrometric analysis) within a predetermined time, based on ion intensity being represented by an ion peak with respect to the mass-to-charge ratio of each ion in the MSn result. An ion detection unit judges isotope-peak from the measured ionized data. Assuming that the MS1 count number of a parent-ion peptide measured during a certain constant time-interval is I, a data processing unit makes the MS2 integration number-of-times or analysis time of the peptide proportional to 1/I.
    • 提供用于电离物质的串联分析系统,对所生成的各种离子类型进行质谱分析,选择和离解离子类型,具有特定质荷比的离子类型,从而重复质谱分析测量 在第n级的离子型离子。 基于离子强度由离子峰相对于质量分数表示,A处理在预定时间内判断用于分析MS(次级质谱分析)旁边的分析的控制内容, 在MS&lt; n&gt;结果中的每个离子的电荷比。 离子检测单元根据测得的电离数据判断同位素峰。 假设在一定的时间间隔期间测量的亲代离子肽的MS 1的计数值为I,则数据处理单元使MS <2> 时间或肽的分析时间与1 / I成比例。
    • 9. 发明授权
    • Sulfonic acid derivative and its pharmaceutical application
    • 磺酸衍生物及其制药应用
    • US5496849A
    • 1996-03-05
    • US244141
    • 1994-05-17
    • Kiyotaka OhnoAtsushi OhtakeShintaro NishioKazuhiro HoshiShunji Tsukamoto
    • Kiyotaka OhnoAtsushi OhtakeShintaro NishioKazuhiro HoshiShunji Tsukamoto
    • C07D307/93A61K31/34C07D307/78C07D307/80
    • C07D307/93
    • The present invention discloses sulfonamide derivative represented by the following general formula: ##STR1## [wherein, R.sub.1 is(i) --COOR.sub.2 (where, R.sub.2 is (1) hydrogen, (2) a pharmacologically acceptable cation, or (3) an alkyl having 1 to 14 carbon atoms) or,(ii) --C(.dbd.O)--R.sub.3 (wherein, R.sub.3 represents an alkyl having 1 to 4 carbon atoms); A is(i) --(CH.sub.2)n-- (wherein, n represents an integer of 0 to 3),(ii) --CH.dbd.CH--, or the group:(iii) --O--C(R.sub.4) (R.sub.5)-- (wherein, R.sub.4 and R.sub.5 represent (1) hydrogen or (2) an alkyl having 1 to 4 carbon atoms, and R.sub.4 and R.sub.5 may be identical or different); and,w is NH or --O--], as well as a thromboxane A2 receptor antagonistic drug having said derivative for its active ingredient.Since the compound of the present invention has excellent thromboxane A2 receptor antagonistic action, it can be used as a thromboxane A2 receptor antagonist of high activity and long duration.
    • PCT No.PCT / JP93 / 01339 Sec。 371日期:1994年5月17日 102(e)日期1994年5月17日PCT提交1993年9月17日PCT公布。 出版物WO94 / 06785 日本3月3日公开本发明公开了由以下通式表示的磺酰胺衍生物:其中,R 1为(ⅰ)-COOR 2(其中,R 2为(1)氢),(2)药理学上可接受的阳离子 ,或(3)具有1至14个碳原子的烷基)或(ii)-C(= O)-R 3(其中,R 3表示具有1至4个碳原子的烷基); A是(i) - (CH 2)n - (其中,n表示0至3的整数),(ii)-CH = CH-或基团:(iii)-OC(R4)(R5) - ( 其中,R4和R5表示(1)氢或(2)具有1至4个碳原子的烷基,R4和R5可以相同或不同); 和w是NH或-O-],以及具有所述衍生物作为其活性成分的血栓素A2受体拮抗药。 由于本发明化合物具有优异的血栓素A2受体拮抗作用,因此可用作活性高且持续时间长的血栓烷A2受体拮抗剂。